Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2020, 56(2): 151
ISSN 1699-3993
Copyright 2020 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2020.56.2.3100503
 
 
JAK inhibitors in chronic plaque psoriasis: What is known so far
Plachouri, K.-M., Georgiou, S.
 
 
Janus kinase (JAK) inhibitors are novel small molecules with a mechanism of action in multiple signaling pathways that allows their application in a broad spectrum of autoimmune and autoinflammatory diseases. As far as the field of dermatology is concerned, chronic plaque psoriasis is currently one of the most studied indications regarding the potential use of JAK inhibitors. The purpose of this review is to provide a summarized overview of the existing information on the efficacy and safety of JAK inhibitors in plaque psoriasis, with a focus on tofacitinib, ruxolitinib, baricitinib, peficitinib and filgotinib. Although the published data on the therapeutic benefit of these agents in the therapy of this chronic condition are promising, further prospective studies and real-life data are necessary in order to sufficiently evaluate their role as an adequate treatment option for psoriatic patients.


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy